Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Rosiglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Cancer, Papillary 2 Polycystic Ovary Syndrome 2 Pituitary Neoplasms 2 Neoplasms 2 Diabetes Mellitus, Type 2 2 Adenocarcinoma, Follicular 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Sezary Syndrome 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Obesity 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Follicular 1 Liposarcoma 1 Leukoplakia, Oral 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Alzheimer Disease 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 22 Radiotherapy 12 Ifosfamide 11 Trabectedin 10 pazopanib 5 Gemcitabine 5 ribociclib 4 pembrolizumab 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 palbociclib 3 eribulin 3 X-Rays 3 Imatinib Mesylate 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 romidepsin 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡